ArticleClinical case reports2026
Epstein-Barr Virus and Hepatitis E Virus in an Immunocompetent Adult: A Rare Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epstein-Barr Virus and Hepatitis E Virus in an Immunocompetent Adult: A Rare Case Report.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus (EBV) and Hepatitis E virus (HEV) are two distinct viral pathogens known to affect the liver. While EBV commonly causes mild, self-limited hepatitis, and HEV is the leading cause of acute viral hepatitis globally, co-infection with both viruses is exceedingly rare. This case report describes a 55-year-old previously healthy male who presented with right upper quadrant abdominal pain and generalized fatigue. Laboratory investigations revealed markedly elevated transaminases and slightly increased bilirubin, suggesting mixed hepatocellular and cholestatic liver injury. Initial serologies showed positive EBV IgG and borderline IgM, confirmed by a low positive EBV DNA PCR. While awaiting HEV testing, the patient was managed supportively. On day four, HEV IgM returned positive and EBV DNA rose to 15,500 copies/mL, confirming concomitant infection. Imaging revealed periportal edema and splenomegaly with no biliary obstruction. Supportive care led to a steady clinical improvement and normalization of liver enzymes by day 14. The patient was discharged in stable condition with full clinical and biochemical recovery. This case highlights the importance of considering dual viral infections in patients with significant hepatic enzyme elevation and non-specific systemic symptoms. Although rare, concurrent EBV and HEV infection can present with significant liver inflammation but may still follow a self-limiting course in immunocompetent individuals. Awareness of such co-infections can prevent misdiagnosis, avoid unnecessary interventions, and emphasize the role of supportive care. Additionally, this case underscores the need for comprehensive viral screening when evaluating unexplained hepatitis in otherwise healthy individuals. Early recognition ensures appropriate management and favorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.